BeOne Medicines (ONC) Other Non-Current Assets (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Other Non-Current Assets of $104.2 million for Q1 2026, down 30.45% year-over-year from $149.9 million in Q1 2025, and up 1.78% quarter-over-quarter from $102.4 million in Q4 2025.
BeOne Medicines (ONC) Other Non-Current Assets (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Other Non-Current Assets for 12 consecutive years, with $104.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 30.45% year-over-year to $104.2 million; the TTM figure through Mar 2026 stood at $104.2 million (down 30.45% YoY), while the FY2025 annual figure was $102.4 million, down 36.18% from the prior year.
- Other Non-Current Assets advanced to $104.2 million in Q1 2026 per ONC's latest filing, from $102.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $201.2 million in Q3 2024 and bottomed at $3.9 million in Q2 2022.
- Historically, Other Non-Current Assets has averaged $121.2 million across 5 years, with a median of $140.6 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 60.32% — and 2024, when it soared 3910.09%.
- BeOne Medicines' Other Non-Current Assets stood at $75.1 million in 2022, then jumped by 66.89% to $125.4 million in 2023, then climbed by 28.02% to $160.5 million in 2024, then sank by 36.18% to $102.4 million in 2025, then increased by 1.78% to $104.2 million in 2026.
- Business Quant data shows ONC's Other Non-Current Assets at $104.2 million in Q1 2026, $102.4 million in Q4 2025, and $136.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.58 Mn |
| Mar 31, 2026 | 104.24 Mn |
| Dec 31, 2025 | 102.42 Mn |
| Sep 30, 2025 | 136.20 Mn |
| Jun 30, 2025 | 161.72 Mn |
| Mar 31, 2025 | 149.89 Mn |
| Dec 31, 2024 | 160.49 Mn |
| Sep 30, 2024 | 201.17 Mn |
| Jun 30, 2024 | 199.32 Mn |
| Mar 31, 2024 | 199.02 Mn |
| Dec 31, 2023 | 125.36 Mn |
| Sep 30, 2023 | 140.90 Mn |
| Jun 30, 2023 | 147.55 Mn |
| Mar 31, 2023 | 4.96 Mn |
| Dec 31, 2022 | 75.12 Mn |
| Sep 30, 2022 | 140.55 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 6.96 Mn |
| Dec 31, 2021 | 7.21 Mn |
| Sep 30, 2021 | 6.06 Mn |